Chief Science Officer Kristi Snell also confirmed as a keynote speaker at upcoming plant meeting
WOBURN, Mass., April 26, 2018 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today highlighted upcoming events in the form of a scientific research paper published in Plant Science, a leading peer-reviewed scientific journal, as well an upcoming presentation at a plant conference in late April. Both opportunities are a result of Yield10’s innovative approach to engineering gene traits designed to increase crop yield, and the Company’s status as a leading voice and thought leader in the agricultural innovation sector.
The paper, entitled “Metabolic Engineering to Increase Crop Yield: From Concept to Execution,” is authored by Yield10 employees and leadership including Frank A. Skraly, Madana M.R. Ambavaram, Oliver Peoples, and Kristi D. Snell, and is part of a special issue of Plant Science, an international journal of experimental plant biology. It discusses how trait discovery programs can benefit from smart approaches that incorporate predictive models to identify novel gene targets to increase yields in key crops. The paper references Yield10’s own trait discovery program, and examines various external factors that impact the cost and timeline to reach commercialization.
On April 28, Chief Science Officer Kristi Snell, Ph.D., will present as one of the keynote speakers at the Northeast Section of The American Association of Plant Biologists (ASPB) 2018 meeting, held at the University of Massachusetts (UMASS), Amherst. At the meeting, she will discuss how step-change increases in crop yield will require innovators to build better plants. Snell will discuss the Company’s multifaceted approach to discovering gene targets that boost plant productivity, including the use of in silico analyses of plant metabolism and gene networks. Yield10 relies on targeted design strategies for plant metabolic engineering, as opposed to the mass screening and trial-and-error approaches that have stagnated the development in this sector within the crop industry for the past 20 years.
“We are pleased to participate in these opportunities to demonstrate and discuss how we apply our unique metabolic engineering skill sets to increase crop yield,” said Kristi Snell, Chief Science Officer at Yield10 Bioscience, Inc. “We believe our trait discovery programs, which incorporate targeted rational design strategies with genome editing tools, are a clear differentiator from existing industry approaches, and will continue to serve as the basis for our research and scientific collaborations with leading universities and agtech companies.”
About Yield10 Bioscience
Yield10 Bioscience, Inc. is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems. Yield10 is leveraging its technology platforms and unique knowledge base to design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and rice. Yield10 is headquartered in Woburn, MA and has an Oilseeds center of excellence in Saskatoon, Canada.
For more information about the company, please visit www.yield10bio.com.
(YTEN-G)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, the use of technology to successfully identify targets for increasing crop yield, the formation of new collaborations and progress by Yield10, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.
Contacts:
Yield10 Bioscience:
Lynne H. Brum, (617) 682-4693, [email protected]
Investor Relations:
Amato and Partners, LLC
[email protected]
Media Inquiries:
Eric Fischgrund
Fischtank Marketing and PR
[email protected]


Same sparkle, different story: how lab-grown diamonds are transforming the market
Japan Earthquake Disrupts Auto and Chip Supply Chains
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
World game at war: why some European nations have threatened a World Cup boycott
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 



